ARRY-380 Size:Solid 2 mg is an orally bioavailable small-molecule

is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

Smiles: CO[C@H]1C=CO[C@@]2(C)OC3=C(C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(C=NN1CCN(CC1)C1CCCC1)=C4O)C2=O |c:25

J Am Assoc Nurse Pract

H2O/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28

ARRY-380 Size:Solid 2 mg is an orally bioavailable small-moleculeARRY 380 analog is an analog of ARRY 380. ARRY 380 is also know as Tucatinib, also known as Irbinitinib, and ONT 380, is a n orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB 2 (also called HER2) with potential antineoplastic activity. ErbB 2 inhibitor ARRY 380 selectively binds to and inhibits the phosphorylation of ErbB 2, which may prevent the activation of ErbB 2 signal transduction pathways,